Arena Pharmaceuticals Inc
ARNA
ARNA was delisted on the 10th of March, 2022.
119 hedge funds and large institutions have $731M invested in Arena Pharmaceuticals Inc in 2017 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 53 increasing their positions, 16 reducing their positions, and 13 closing their positions.
231% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 16
138% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 13
138% more capital invested
Capital invested by funds: $307M → $731M (+$425M)
118% more call options, than puts
Call options by funds: $32.6M | Put options by funds: $14.9M
17% more funds holding
Funds holding: 102 → 119 (+17)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$71.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$20.4M |
| 3 |
BlackRock
New York
|
+$16M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.7M |
| 5 |
DM
Deerfield Management
New York
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$24.8M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$7.17M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.21M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
-$1.93M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.65M |
ARNA Hedge Fund Activity: Q3 2017 in Review
119 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q3 2017, worth a combined $731M — up 138% from $307M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ARNA positions and 13 closed out — a net gain of 18 holders — while 53 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $71.4M. The largest seller was Great Point Partners, cutting an estimated $24.8M.
- 119 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q3 2017, up from 102 in Q2 2017.
- Funds reported $731M of Arena Pharmaceuticals Inc stock for Q3 2017, up 138% quarter-over-quarter.
- 31 funds opened new Arena Pharmaceuticals Inc positions in Q3 2017 and 13 closed out, a net change of +18 holders.
- The largest Arena Pharmaceuticals Inc buyer in Q3 2017 was Fidelity Investments, an estimated $71.4M added.
- The largest Arena Pharmaceuticals Inc seller in Q3 2017 was Great Point Partners, an estimated $24.8M sold.
Based on aggregated 13F filings for Q3 2017.